1
|
MacManus M, Fisher R, Roos D, O'Brien P, Macann A, Tsang R, Davis S, Christie D, McClure B, Joseph D, Seymour J. SYSTEMIC THERAPY AFTER RADIATION THERAPY IN STAGE I-II FOLLICULAR LYMPHOMA: FINAL RESULTS OF AN INTERNATIONAL RANDOMIZED TRIAL TROG 99.03. Hematol Oncol 2019. [DOI: 10.1002/hon.35_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- M.P. MacManus
- Radiation Oncology; Peter MacCallum Cancer Centre; Melbourne Australia
| | - R. Fisher
- Radiation Oncology; Peter MacCallum Cancer Centre; Melbourne Australia
| | - D. Roos
- Radiation Oncology; Royal Adelaide Hospital; Adelaide Australia
| | - P. O'Brien
- Radiation Oncology; GenesisCare Lake Macquarie Private Hospital; Gateshead Australia
| | - A. Macann
- Radiation Oncology; Auckland City Hospital; Auckland New Zealand
| | - R. Tsang
- Radiation Oncology; Princess Margaret Hospital; Toronto Canada
| | - S. Davis
- Radiation Oncology; Alfred Hospital; Melbourne Australia
| | - D. Christie
- Radiation Oncology; Genesis Care Premion; Southport Australia
| | - B. McClure
- Radiation Oncology; Peter MacCallum Cancer Centre; Melbourne Australia
| | - D. Joseph
- Radiation Oncology; Sir Charles Gairdner Hospital; Perth Australia
| | - J. Seymour
- Haematology; Peter MacCallum Cancer Centre; Melbourne Australia
| |
Collapse
|
2
|
Macmanus M, Fisher R, Roos D, O'Brien P, Macann A, Tsang R, Davis S, Christie D, McClure B, Joseph D, Seymour J. CVP OR R-CVP GIVEN AFTER INVOLVED-FIELD RADIOTHERAPY IMPROVES PROGRESSION FREE SURVIVAL IN STAGE I-II FOLLICULAR LYMPHOMA: RESULTS OF AN INTERNATIONAL RANDOMIZED TRIAL. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_11] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M.P. Macmanus
- Radiation Oncology; Peter MacCallum Cancer Centre; Melbourne Australia
| | - R. Fisher
- Radiation Oncology; Peter MacCallum Cancer Centre; Melbourne Australia
| | - D. Roos
- Radiation Oncology; Royal Adelaide Hospital; Adelaide Australia
| | - P. O'Brien
- Radiation Oncology; Genesis Healthcare; Gateshead Australia
| | - A. Macann
- Radiation Oncology; Auckland City Hospital; Auckland New Zealand
| | - R. Tsang
- Radiation Oncology; Princess Margaret Hospital; Toronto Canada
| | - S. Davis
- Radiation Oncology; Alfred Hospital; Melbourne Australia
| | - D. Christie
- Radiation Oncology; Genesis CancerCare Southport; Southport Australia
| | - B. McClure
- Radiation Oncology; Peter MacCallum Cancer Centre; Melbourne Australia
| | - D. Joseph
- Radiation Oncology; Sir Charles Gairdner Hospital; Perth Australia
| | - J.F. Seymour
- Haematology; Peter MacCallum Cancer Centre; Melbourne Australia
| |
Collapse
|
3
|
Michael M, Chander S, McKendrick J, MacKay JR, Steel M, Hicks R, Heriot A, Leong T, Cooray P, Jefford M, Zalcberg J, Bressel M, McClure B, Ngan SY. Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancer. Br J Cancer 2014; 111:1924-31. [PMID: 25211659 PMCID: PMC4229632 DOI: 10.1038/bjc.2014.487] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2014] [Revised: 07/29/2014] [Accepted: 08/13/2014] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND Patients (pts) with metastatic rectal cancer and symptomatic primary, require local and systemic control. Chemotherapy used during chemoradiotherapy (CRT) is adequate for radiosensitisation, but suboptimal for systemic control. The aim of this phase II study was to assess tolerability, local/systemic benefits, of a novel regimen delivering interdigitating intensive chemotherapy with radical CRT. METHODS Eligible pts had untreated synchronous symptomatic primary/metastatic rectal cancer. A total of 12 weeks of treatment with split-course pelvic CRT (total 50.4 Gy with concurrent oxaliplatin and 5-FU infusion) alternating with FOLFOX chemotherapy. All pts staged with CT, MRI and FDG-PET pre and post treatment. RESULTS Twenty-six pts were treated. Rectal primary MRI stage: T3 81% and T4 15%. Liver metastases in 81%. Twenty-four pts (92%) completed the 12-week regimen. All patients received planned RT dose, and for both agents over 88% of patients achieved a relative dose intensity of >75%. Grade 3 toxicities: neutropenia 23%, diarrhoea 15%, and radiation skin reaction 12%. Grade 4 toxicity: neutropenia 15%. FDG-PET metabolic response rate for rectal primary 96%, and for metastatic disease 60%. CONCLUSIONS Delivery of interdigitating chemotherapy with radical CRT was feasible to treat both primary and metastatic rectal cancer. High completion and response rates were encouraging.
Collapse
Affiliation(s)
- M Michael
- Division of Cancer Medicine, Lower Gastrointestinal Tumour Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
- The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Melbourne, Victoria, Australia
| | - S Chander
- Division of Radiation Oncology, Lower Gastrointestinal Tumour Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - J McKendrick
- Department of Medical Oncology, Box Hill Hospital, Melbourne, Victoria, Australia
| | - J R MacKay
- Division of Surgical Oncology, Lower Gastrointestinal Tumour Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - M Steel
- Department of Surgery, Box Hill Hospital, Melbourne, Victoria, Australia
| | - R Hicks
- The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Melbourne, Victoria, Australia
- Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - A Heriot
- Division of Surgical Oncology, Lower Gastrointestinal Tumour Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - T Leong
- Division of Radiation Oncology, Lower Gastrointestinal Tumour Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - P Cooray
- Department of Medical Oncology, Box Hill Hospital, Melbourne, Victoria, Australia
| | - M Jefford
- Division of Cancer Medicine, Lower Gastrointestinal Tumour Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
- The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Melbourne, Victoria, Australia
| | - J Zalcberg
- Division of Cancer Medicine, Lower Gastrointestinal Tumour Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - M Bressel
- Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - B McClure
- Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - S Y Ngan
- Division of Radiation Oncology, Lower Gastrointestinal Tumour Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| |
Collapse
|
4
|
Ngan S, Fisher R, Burmeister B, Mackay J, McLachlan S, Beresford J, McClure B, Goldstein D, Joseph D, Solomon M. Long-term Quality of Life in Patients Treated in TROG 01.04: A Randomized Trial Comparing Short Course and Long Course Preoperative Radiation Therapy for Rectal Cancer. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.371] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
5
|
Nagareddy PR, Rajput PS, Vasudevan H, McClure B, Kumar U, Macleod KM, McNeill JH. Inhibition of matrix metalloproteinase-2 improves endothelial function and prevents hypertension in insulin-resistant rats. Br J Pharmacol 2012; 165:705-15. [PMID: 21740410 DOI: 10.1111/j.1476-5381.2011.01583.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND AND PURPOSE Insulin resistance is often found to be associated with high blood pressure. We propose that in insulin-resistant hypertension, endothelial dysfunction is the consequence of increased activity of vascular MMP-2. As MMP-2 proteolytically cleaves a number of extracellular matrix proteins, we hypothesized that MMP-2 impairs endothelial function by proteolytic degradation of endothelial NOS (eNOS) or its cofactor, heat shock protein 90 (HSP90). EXPERIMENTAL APPROACH We tested our hypothesis in bovine coronary artery endothelial cells and fructose-fed hypertensive rats (FHR), a model of acquired systolic hypertension and insulin resistance. KEY RESULTS Treatment of FHRs with the MMP inhibitor doxycycline, preserved endothelial function as well as prevented the development of hypertension, suggesting that MMPs impair endothelial function. Furthermore, incubating endothelial cells in vitro with a recombinant MMP-2 decreased NO production in a dose-dependent manner. Using substrate cleavage assays and immunofluorescence microscopy studies, we found that MMP-2 not only cleaves and degrades HSP90, an eNOS cofactor but also co-localizes with both eNOS and HSP90 in endothelial cells, suggesting that MMPs functionally interact with the eNOS system. Treatment of FHRs with doxycycline attenuated the decrease in eNOS and HSP90 expression but did not improve insulin sensitivity. CONCLUSIONS AND IMPLICATIONS Our data suggest that increased activity of MMP-2 in FHRs impairs endothelial function and promotes hypertension. Inhibition of MMP-2 could be a potential therapeutic strategy for the management of hypertension.
Collapse
Affiliation(s)
- P R Nagareddy
- Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada
| | | | | | | | | | | | | |
Collapse
|
6
|
Nqan S, McKendrick J, Bressel M, Leong T, Cooray P, Heriot A, Steel M, Chander S, McClure B, Michael M. 6050 POSTER A 12-week Regimen With Interdigitating FOLFOX Chemotherapy and Pelvic Chemoradiation for Simultaneous Primary and Metastatic Rectal Cancer. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71695-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
7
|
Ngan S, Fisher R, Goldstein D, Solomon M, Burmeister B, Ackland SP, Joseph DJ, McClure B, McLachlan S, Mackay J. A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: An intergroup trial (TROG, AGITG, CSSANZ, RACS). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3509] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
8
|
Narayan K, Rischin D, Quinn M, Goh JC, Cheuk R, Obermair A, Bernshaw D, McClure B, Milner A, Mileshkin LR. Adjuvant chemotherapy and chemoradiation following surgery for high-risk endometrial cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.5028] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
McLachlan S, Fisher R, McClure B, Beresford J, McKendrick J, Mackay J, Solomon M, Burmeister B, Hartopeanu C, Ngan S. A comparison of quality of life in patients with T3 rectal cancer receiving short course versus long course preoperative radiation. A Trans-Tasman Radiation Oncology Group Trial (TROG 01.04). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.4097] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
10
|
Dickerson RR, Li C, Li Z, Marufu LT, Stehr JW, McClure B, Krotkov N, Chen H, Wang P, Xia X, Ban X, Gong F, Yuan J, Yang J. Aircraft observations of dust and pollutants over northeast China: Insight into the meteorological mechanisms of transport. ACTA ACUST UNITED AC 2007. [DOI: 10.1029/2007jd008999] [Citation(s) in RCA: 81] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
11
|
Ngan S, Fisher R, Mackay J, Solomon M, Burmeister B, Goldstein D, Schache D, Joseph D, Ackland S, McClure B. 3008 ORAL Acute adverse events in a randomised trial of short course versus long course preoperative radiotherapy for T3 adenocarcinoma of rectum: a Trans-Tasman Radiation Oncology Group trial (TROG 01.04). EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70936-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
12
|
Rischin D, Narayan K, Oza A, Mileshkin L, Bernshaw D, Hanlon K, McClure B, Fyles A. A phase I study of tirapazamine in combination with radiation and weekly cisplatin in patients with locally advanced cervical cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.5543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5543 Background and Purpose: Hypoxia is an adverse prognostic factor in locoregionally advanced cervical cancer treated with radiation. GOG are currently studying the hypoxic cytotoxin, tirapazamine (TPZ) in combination with biweekly intermediate dose cisplatin (CIS) and radiation in a large phase III trial. The aim of this phase I study was to develop a better tolerated regimen that added TPZ to the standard regimen of radiation and weekly low dose CIS. Methods: Eligible patients had previously untreated carcinoma of the cervix, Stages IB2 - IVA. The starting schedule was radiotherapy (45 to 50.4 Gy external beam radiation followed by brachytherapy), with concomitant weekly CIS 40 mg/m2 weeks 1–6 and weekly TPZ 290 mg/m2 (prior to CIS) in weeks 1–5. Results: Between 3/05 and 7/06 eleven patients were enrolled, median age (range) 52 (31–65), squamous cell carcinoma 10, adenocarcinoma 1, 1B2–5, IIA-1, IIB-3, IIIB- 1, IVA-1. The first 2 patients on dose level 1 experienced a dose limiting toxicity (DLT), one grade 3 ALT (SGPT) elevation and grade 4 pulmonary embolism and one grade 3 ototoxicity. Doses were decreased to dose level -1 CIS 30 mg/m2 and TPZ 260 mg/m2. Three patients were treated without any DLTs. Six patients were then treated on dose level -1a, CIS 35 mg/m2 and TPZ 260 mg/m2, with 2 DLTs: grade 3 neutropenia with dose omission and grade 4 pulmonary embolism with major hemodynamic compromise. The sixth patient on dose level -1a withdrew from the trial in week 2 after being advised about the DLTs observed on this dose level. 3 additional patients will be accrued on dose level -1 to confirm safety of this dose level. One patient has relapsed in pelvic nodes, all other patients remain disease-free with a median followup of 10 months (range 5 - 21) Conclusions: The combination of weekly TPZ and CIS with radiation for locally advanced cervical cancer was associated with more toxicity than anticipated with the recommended dose level being TPZ 260 mg/m2, CIS 30 mg/m2. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- D. Rischin
- Peter McCallum Cancer Centre, Melbourne, Australia; Princess Margaret Hospital, Toronto, ON, Canada
| | - K. Narayan
- Peter McCallum Cancer Centre, Melbourne, Australia; Princess Margaret Hospital, Toronto, ON, Canada
| | - A. Oza
- Peter McCallum Cancer Centre, Melbourne, Australia; Princess Margaret Hospital, Toronto, ON, Canada
| | - L. Mileshkin
- Peter McCallum Cancer Centre, Melbourne, Australia; Princess Margaret Hospital, Toronto, ON, Canada
| | - D. Bernshaw
- Peter McCallum Cancer Centre, Melbourne, Australia; Princess Margaret Hospital, Toronto, ON, Canada
| | - K. Hanlon
- Peter McCallum Cancer Centre, Melbourne, Australia; Princess Margaret Hospital, Toronto, ON, Canada
| | - B. McClure
- Peter McCallum Cancer Centre, Melbourne, Australia; Princess Margaret Hospital, Toronto, ON, Canada
| | - A. Fyles
- Peter McCallum Cancer Centre, Melbourne, Australia; Princess Margaret Hospital, Toronto, ON, Canada
| |
Collapse
|
13
|
Juergensen P, Eras J, McClure B, Kliger AS, Finkelstein FO. The impact of various cycling regimens on phosphorus removal in chronic peritoneal dialysis patients. Int J Artif Organs 2006; 28:1219-23. [PMID: 16404697 DOI: 10.1177/039139880502801204] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND The National Kidney Foundation Dialysis Outcome Quality Initiative clinical practice guidelines have suggested that serum phosphate levels be maintained at < or =5.5 mg/dL in patients maintained on dialysis. Over 45% of anuric patients maintained on CAPD have serum phosphate levels >5.5 mg/dL. The present study was designed to address the question whether phosphate removal could be enhanced by increasing the dialysate volume during cycler peritoneal dialysis therapy. METHODS Medically stable patients maintained on chronic peritoneal dialysis therapy, who were high or high-average transporters and had serum phosphate levels > or =5.5 mg/dL, were invited to participate in the study. The protocol involved measuring phosphate and creatinine clearances at weekly intervals on three different cycler prescriptions consisting of 7 and 12 full cycles or 24 cycles with 50% tidal PD (TPD) over 9 hours. Ten patients agreed to participate. Those patients (n=7) with a BMI > 22 had 2 liter (L) fill volumes and 14 L of total dialysate (7 cycles of 2 L) or 24 L total dialysate (12 cycles of 2 L or 50% TPD with 24 cycles).The patients (n=3) with a BMI < 20 had 1.2 L fill volumes and 8.4 L total dialysate (7 cycles) or 14.4 L total dialysate (12 cycles of 1.2 L or 50% TPD with 24 cycles). RESULTS The mean age (+/- SD) of the study patients was 50.8 (+/- 9.3) years. There were 6 females, 6 Caucasians and 4 African-Americans. The mean weight of the patients was 71.5 (+/- 24.2) kg and mean height 1.65 (+ 7.6) meters. The mean BMI was 18.3 (+/- 1.27) in the < 20 BMI group and 30.3 (+/- 6.6) in the > 22 BMI group. The mean phosphate clearance (L/night/1.73m 2 ) increased from 3.96 (+/- 1.16) with 7 cycles to 4.71 (+ 1.81) with 12 cycles and 4.51 (+/- 1.61) with 50% TPD. Creatinine clearance (L/night/1.73m 2 ) was 4.74 (+/- 1.74) with 7 cycles, 6.06 (+/- 2.04) with 12 cycles and 5.61 (+/- 2.01) with TPD. CONCLUSION The present study indicates that there is a significant, 19% (P < 0.005) rise in phosphate clearance by increasing dialysate volume 71% from 7 cycles to 14 cycles compared to a 27% increase in creatinine clearance. With tidal PD, phosphate clearance increased by 12% (p=NS) and creatinine clearance increased 18 % (p, 0.02). This increase in phosphate clearance translates into <50 mg net phosphate removal in 9 hours, assuming a serum phosphate of 6 mg/%. Thus, increasing dialysis cycles and volume results in only a minimal increase in net phosphate removal.
Collapse
Affiliation(s)
- P Juergensen
- New Haven CAPD, Renal Research Institute, Division of Nephrology, Departments of Internal Medicine, Hospital of St. Raphael, Yale University School of Medicine, New Haven, CT, USA
| | | | | | | | | |
Collapse
|
14
|
|
15
|
Ngan S, Fisher R, Burmeister B, Rischin D, Mackay J, Kneebone A, Joseph D, McKendrick J, Goldstein D, McClure B, Lim Joon D. Delayed relapse following preoperative chemoradiation and surgery for rectal cancer. Int J Radiat Oncol Biol Phys 2003. [DOI: 10.1016/s0360-3016(03)01035-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
16
|
McClure B, Stomski F, Lopez A, Woodcock J. Perverted responses of the human granulocyte-macrophage colony-stimulating factor receptor in mouse cell lines due to cross-species beta-subunit association. Blood 2001; 98:3165-8. [PMID: 11698308 DOI: 10.1182/blood.v98.10.3165] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Transfected murine cell lines are commonly used to study the function of many human cytokine or receptor mutants. This study reports the inappropriate activation of the human granulocyte-macrophage colony-stimulating factor (hGM-CSF) receptor by the human GM-CSF antagonist, E21R, when the human receptor is introduced into the murine cell line BaF-B03. E21R-induced proliferation of the BaF-B03 cells is dependent on transfection with both hGM-CSF receptor alpha and beta(c) subunits. Studies on the underlying mechanism revealed constitutive association between human and mouse beta(c) and GM-CSF receptor-alpha, tyrosine phosphorylation of mouse and human beta(c), and association of phosphorylated mouse beta(c) into an activated human GM-CSF receptor complex in response to E21R and GM-CSF. This interspecies receptor cross-talk of receptor signaling subunits may produce misleading results and emphasizes the need to use cell lines devoid of the cognate endogenous receptors for functional analysis of ligand and receptor mutants.
Collapse
Affiliation(s)
- B McClure
- Cytokine Receptor Laboratory, Hanson Centre for Cancer Research, Institute of Medical and Veterinary Science, Adelaide, South Australia
| | | | | | | |
Collapse
|
17
|
|
18
|
Rischin D, Boyer M, Smith J, Millward M, Michael M, Bishop J, Zalcberg J, Davison J, Emmett E, McClure B. A phase I trial of docetaxel and gemcitabine in patients with advanced cancer. Ann Oncol 2000; 11:421-6. [PMID: 10847460 DOI: 10.1023/a:1008384326701] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Docetaxel and gemcitabine are active in a broad range of malignancies. The objective of this phase I trial was to determine the maximally tolerated doses of the combination of docetaxel and gemcitabine. PATIENTS AND METHODS Patients with advanced cancer, WHO performance status 0-2, who had received up to one prior chemotherapy regimen were treated with gemcitabine on days 1 and 8 and docetaxel on day 8 repeated every 21 days. Prophylactic ciprofloxacin was commenced on day 11 of each cycle and continued until the neutrophil count reached 1.0 x 10(9)/l. G-CSF was not administered. Dose levels studied were docetaxel/gemcitabine: 60/800, 60/1000, 75/1000, 75/1200, 85/1200 and 100/1200 mg/m2. RESULTS Thirty-nine patients were entered and all were assessable for toxicity. The highest administered dose level was 100 mg/m2 docetaxel and 1200 mg/m2 gemcitabine with dose limiting toxicities of febrile neutropenia, grade 4 neutropenia > or = 7 days, grade 4 thrombocytopenia, grade 3 stomatitis and/or grade 3 fatigue in three out of six patients. Treatment was well tolerated (40 cycles) in the 10 patients treated at the recommended dose level (85/1200) with only a single episode of febrile neutropenia and grade 3 or 4 non-hematologic toxicity was infrequent. There was no significant pulmonary toxicity. Responses were seen in a range of malignancies including non-small-cell lung cancer. CONCLUSIONS The recommended dose level of 85 mg/m2 docetaxel and 1200 mg/m2 gemcitabine has a favourable toxicity profile and is suitable for further investigation in phase II trials. This non-platinum containing regimen warrants further investigation as a potential alternative to platinum containing regimens in non-small-cell lung cancer and other malignancies.
Collapse
Affiliation(s)
- D Rischin
- Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Australia.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Craig S, Morris K, Tubman T, McClure B. The fetal and neonatal outcomes of Rhesus D antibody affected pregnancies in Northern Ireland. Ir Med J 2000; 93:17-8. [PMID: 10740367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
It has been suggested that routine antenatal prophylactic anti-D should be introduced for prevention of Rhesus D (RhD) haemolytic disease. Before making changes to the current prevention program it is important, therefore, to have up-to-date data on affected infants. Pregnant women with anti-D antibodies between September 1994 and February 1997 were identified by the Northern Ireland Blood Transfusion Service. The records of 124 women and 130 babies were examined. 26% of planned deliveries occurred in hospitals without paediatric cover. Rhesus isoimmunisation affected 78 babies. Fifty-nine infants were admitted to one of seven neonatal units. There were 2 stillbirths and 1 neonatal death. Two infants have severe neurodevelopmental delay. There is still significant morbidity associated with RhD haemolytic disease. Care for RhD affected pregnancies should be centralised to guarantee training opportunities and maintenance of expertise. The current management of these pregnancies should be re-examined before changing the Rhesus prevention program.
Collapse
Affiliation(s)
- S Craig
- Department of Child Health, Queen's University of Belfast, N. Ireland
| | | | | | | |
Collapse
|
20
|
McClure B, Mou B, Canevascini S, Bernatzky R. A small asparagine-rich protein required for S-allele-specific pollen rejection in Nicotiana. Proc Natl Acad Sci U S A 1999; 96:13548-53. [PMID: 10557358 PMCID: PMC23985 DOI: 10.1073/pnas.96.23.13548] [Citation(s) in RCA: 114] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/1999] [Indexed: 11/18/2022] Open
Abstract
Although S-locus RNases (S-RNases) determine the specificity of pollen rejection in self-incompatible (SI) solanaceous plants, they alone are not sufficient to cause S-allele-specific pollen rejection. To identify non-S-RNase sequences that are required for pollen rejection, a Nicotiana alata cDNA library was screened by differential hybridization. One clone, designated HT, hybridized strongly to RNA from N. alata styles but not to RNA from Nicotiana plumbaginifolia, a species known to lack one or more factors necessary for S-allele-specific pollen rejection. Sequence analysis revealed a 101-residue ORF including a putative secretion signal and an asparagine-rich domain near the C terminus. RNA blot analysis showed that the HT-transcript accumulates in the stigma and style before anthesis. The timing of HT-expression lags slightly behind S(C10)-RNase in SI N. alata S(C10)S(C10) and is well correlated with the onset of S-allele-specific pollen rejection in the style. An antisense-HT construct was prepared to test for a role in pollen rejection. Transformed (N. plumbaginifolia x SI N. alata S(C10)S(C10)) hybrids with reduced levels of HT-protein continued to express S(C10)-RNase but failed to reject S(C10)-pollen. Control hybrids expressing both S(C10)-RNase and HT-protein showed a normal S-allele-specific pollen rejection response. We conclude that HT-protein is directly implicated in pollen rejection.
Collapse
Affiliation(s)
- B McClure
- Department of Biochemistry, University of Missouri, 117 Schweitzer Hall, Columbia, MO 65211, USA.
| | | | | | | |
Collapse
|
21
|
Sun Q, Jones K, McClure B, Cambareri B, Zacharakis B, Iversen PO, Stomski F, Woodcock JM, Bagley CJ, D'Andrea R, Lopez AF. Simultaneous antagonism of interleukin-5, granulocyte-macrophage colony-stimulating factor, and interleukin-3 stimulation of human eosinophils by targetting the common cytokine binding site of their receptors. Blood 1999; 94:1943-51. [PMID: 10477723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023] Open
Abstract
Human interleukin-5 (IL-5), granulocyte-macrophage colony-stimulating factor (GM-CSF), and IL-3 are eosinophilopoietic cytokines implicated in allergy in general and in the inflammation of the airways specifically as seen in asthma. All 3 cytokines function through cell surface receptors that comprise a ligand-specific alpha chain and a shared subunit (beta(c)). Although binding of IL-5, GM-CSF, and IL-3 to their respective receptor alpha chains is the first step in receptor activation, it is the recruitment of beta(c) that allows high-affinity binding and signal transduction to proceed. Thus, beta(c) is a valid yet untested target for antiasthma drugs with the added advantage of potentially allowing antagonism of all 3 eosinophil-acting cytokines with a single compound. We show here the first development of such an agent in the form of a monoclonal antibody (MoAb), BION-1, raised against the isolated membrane proximal domain of beta(c). BION-1 blocked eosinophil production, survival, and activation stimulated by IL-5 as well as by GM-CSF and IL-3. Studies of the mechanism of this antagonism showed that BION-1 prevented the high-affinity binding of (125)I-IL-5, (125)I-GM-CSF, and (125)I-IL-3 to purified human eosinophils and that it bound to the major cytokine binding site of beta(c). Interestingly, epitope analysis using several beta(c) mutants showed that BION-1 interacted with residues different from those used by IL-5, GM-CSF, and IL-3. Furthermore, coimmunoprecipitation experiments showed that BION-1 prevented ligand-induced receptor dimerization and phosphorylation of beta(c), suggesting that ligand contact with beta(c) is a prerequisite for recruitment of beta(c), receptor dimerization, and consequent activation. These results demonstrate the feasibility of simultaneously inhibiting IL-5, GM-CSF, and IL-3 function with a single agent and that BION-1 represents a new tool and lead compound with which to identify and generate further agents for the treatment of eosinophil-dependent diseases such as asthma.
Collapse
MESH Headings
- Animals
- Binding Sites
- CHO Cells
- Cell Survival/drug effects
- Cricetinae
- Eosinophils/cytology
- Eosinophils/drug effects
- Eosinophils/physiology
- Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology
- Humans
- In Vitro Techniques
- Interleukin-3/pharmacology
- Interleukin-5/pharmacology
- Kinetics
- Leukocytes/cytology
- Leukocytes/physiology
- Lymphocyte Activation
- Monocytes/cytology
- Monocytes/physiology
- Neutrophils/cytology
- Neutrophils/physiology
- Receptors, Granulocyte-Macrophage Colony-Stimulating Factor/chemistry
- Receptors, Granulocyte-Macrophage Colony-Stimulating Factor/drug effects
- Receptors, Granulocyte-Macrophage Colony-Stimulating Factor/physiology
- Receptors, Interleukin/chemistry
- Receptors, Interleukin/drug effects
- Receptors, Interleukin/physiology
- Receptors, Interleukin-3/chemistry
- Receptors, Interleukin-3/drug effects
- Receptors, Interleukin-3/physiology
- Receptors, Interleukin-5
- Recombinant Proteins/metabolism
- Recombinant Proteins/pharmacology
- Transfection
Collapse
Affiliation(s)
- Q Sun
- Hanson Centre for Cancer Research, the Institute of Medical and Veterinary Science, Adelaide, Australia
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Abstract
In self-incompatible plants of the Solanaceae, the specificity of pollen rejection is controlled by a single multiallelic S-locus. Pollen tube growth is inhibited in the style when its single S-allele matches either S-allele present in the diploid pistil. Each S-allele encodes an S-RNase with a unique sequence. S-RNases are secreted into the extra-cellular matrix of the transmitting tract which guides pollen tubes toward the ovary. Although it is known that S-RNases are the determinants of S-allele specificity in the pistil, it is not known how allele-specific information is encoded in the sequence. Therefore, we exchanged domains between S-RNases with different recognition specificities and expressed the chimeric proteins in transgenic plants to determine their effects on pollination behavior. Nine chimeric constructs were prepared in which domains from Nicotiana alata SA2- and SC10-RNases were exchanged. Among these nine constructs, the entire S-RNase sequence was sampled by exchanging single variable domains as well as larger blocks of contiguous sequences. The chimeric S-RNases retained enzymatic activity and were expressed at levels comparable to control transformants expressing SA2- and SC10-RNases. However, none of the chimeric S-RNases caused rejection of either SA2- or SC10-pollen. We conclude that the recognition function of S-RNases can be disrupted by alterations in many parts of the sequence. It appears that the recognition function of S-RNase is not localized to a specific domain.
Collapse
Affiliation(s)
- D M Zurek
- Department of Biochemistry, University of Missouri-Columbia 65211, USA
| | | | | | | |
Collapse
|
23
|
Wardell D, Campbell J, Oliver C, McClure B. Nursing intervention with battered women. Abuse often increases with pregnancy. NAACOG Newsl 1992; 19:1, 6-7. [PMID: 1625691] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
24
|
Abstract
One hundred patients having elective cataract surgery were evaluated in a prospective, randomized, double-blinded study comparing retrobulbar and peribulbar anesthesia. Patients were divided into two study groups and evaluated on three criteria felt to be critical to intraocular surgery. Results showed that the efficacy of the one-injection-site peribulbar block was similar to that of the retrobulbar block for all three criteria. Because the one-injection-site anesthetic is administered outside the muscle cone, the potential for optic nerve and central nervous system complications should be minimized.
Collapse
Affiliation(s)
- J C Whitsett
- Dean A. McGee Eye Institute, Department of Ophthalmology, Oklahoma City, Oklahoma 73104
| | | | | |
Collapse
|